Pathophysiology, diagnosis and treatment of dry eye;Pathophysiologie, diagnostik und therapie des trockenen Auges

Deutsches Arzteblatt International

Volumn 112, Issue 5, 2015, Pages 71-82

  Messmer, Elisabeth M ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DRY EYE; PATHOPHYSIOLOGY; ANAMNESIS; CLASSIFICATION; DRY EYE SYNDROMES; HUMAN; PROCEDURES; SLIT LAMP;

ANTIINFLAMMATORY AGENT; ARTIFICIAL TEAR;

ANTI-INFLAMMATORY AGENTS; DRY EYE SYNDROMES; HUMANS; LUBRICANT EYE DROPS; MEDICAL HISTORY TAKING; SLIT LAMP;

EID: 84922051747     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop. Ocul Surf 2007; 5: 75-92.
2. Stern ME, Schaumburg CS, Pflugfelder SC: Dry eye as a mucosal autoimmune disease. Int Rev Immunol 2013; 32: 19-41.
3. Stevenson W, Chauhan SK, Dana R: Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 2012; 130: 90-100.
4. Lemp MA, Crews LA, Bron AJ, Foulks GN, Sullivan BD: Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea 2012; 31: 472-8.
5. Chia EM, Mitchell P, Rochtchina E, Lee AJ, Maroun R, Wang JJ: Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Exp Ophthalmol 2003; 31: 229-32.
6. Schaumberg DA, Sullivan DA, Buring JE, Dana MR: Prevalence of dry eye syndrome among US women. Am J Ophthalmol 2003; 136: 318-26.
7. Ruprecht KW, Giere W, Wulle KG: Statistical contribution on symptomatic dry eye. Ophthalmologica 1977; 174: 65-74.
8. Bron AJ, Tomlinson A, Foulks GN, et al.: Rethinking dry eEye disease: A perspective on clinical implications. Ocul Surf 2014; 12: 1-31.
9. Ridder WH 3rd, Zhang Y, Huang JF: Evaluation of reading speed and contrast sensitivity in dry eye disease. Optom Vis Sci 2013; 90: 37-44.
10. Deschamps N, Ricaud X, Rabut G, Labbe A, Baudouin C, Denoyer A: The impact of dry eye disease on visual performance while driving. Am J Ophthalmol 2013; 156: 184-9.
11. Li M, Gong L, Chapin WJ, Zhu M: Assessment of vision-related quality of life in dry eye patients. Invest Ophthalmol Vis Sci 2012; 53: 5722-7.
12. Schiffman RM, Walt JG, Jacobsen G, Doyle JJ, Lebovics G, Sumner W: Utility assessment among patients with dry eye disease. Ophthalmology 2003; 110: 1412-9.
13. Labbe A, Wang YX, Jie Y, Baudouin C, Jonas JB, Xu L: Dry eye disease, dry eye symptoms and depression: the Beijing Eye Study. Br J Ophthalmol 2013; 97: 1399-403.
14. Yu J, Asche CV, Fairchild CJ: The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea 2011; 30: 379-87.
15. Foulks GN, Bron AJ: Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf 2003; 1: 107-26.
16. Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye Work-Shop (2007). Ocul Surf 2007; 5: 163-78.
17. Sullivan BD, Crews LA, Messmer EM, et al.: Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications. Acta Ophthalmol 2014; 92: 161-6.
18. Methodologies to diagnose and monitor dry eye disease: Report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5: 108-52.
19. Johnston PR, Rodriguez J, Lane KJ, Ousler G, Abelson MB: The interblink interval in normal and dry eye subjects. Clin Ophthalmol 2013; 7: 253-9.
20. Arita R, Itoh K, Inoue K, Amano S: Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology 2008; 115: 911-5.
21. Nemeth J, Fodor E, Lang Z, et al.: Lid-parallel conjunctival folds (LIPCOF) and dry eye: a multicentre study. Br J Ophthalmol 2012; 96: 1380-5.
22. Höh H, Schirra F, Kienecker C, Ruprecht KW: Lid-parallel conjunctival folds are a sure diagnostic sign of dry eye. Ophthalmologe 1995; 92: 802-8.
23. Jacobi C, Cursiefen C: Ophthalmological complications in Sjogren's syndrome. Z Rheumatol 2010; 69: 32-40.
24. Vitali C, Bombardieri S, Jonsson R, et al.: Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61: 554-8.
25. Liew MS, Zhang M, Kim E, Akpek EK: Prevalence and predictors of Sjogren's syndrome in a prospective cohort of patients with aqueous-deficient dry eye. Br J Ophthalmol 2012; 96: 1498-503.
26. Messmer EM: Preservatives in ophthalmology. Ophthalmologe 2012; 109: 1064-70.
27. Lee SY, Tong L: Lipid-containing lubricants for dry eye: a systematic review. Optom Vis Sci 2012; 89: 1654-61.
28. Geerling G, Unterlauft JD, Kasper K, Schrader S, Opitz A, Hartwig D: Autologous serum and alternative blood products for the treatment of ocular surface disorders. Ophthalmologe 2008; 105: 623-31.
29. Celebi AR, Ulusoy C, Mirza GE: The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind cross over study. Graefes Arch Clin Exp Ophthalmol 2014; 252: 619-26.
30. Marsh P, Pflugfelder SC: Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology 1999; 106: 811-6.
31. Pflugfelder SC, Maskin SL, Anderson B, et al.: A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004; 138: 444-57.
32. Sall K, Stevenson OD, Mundorf TK, Reis BL: Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000; 107: 631-9.
33. Yoo SE, Lee DC, Chang MH: The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction. Korean J Ophthalmol 2005; 19: 258-63.
34. Sadrai Z, Hajrasouliha AR, Chauhan S, Saban DR, Dastjerdi MH, Dana R: Effect of topical azithromycin on corneal innate immune responses. Invest Ophthalmol Vis Sci 2011; 52: 2525-31.
35. Foulks GN, Borchman D, Yappert M, Kim SH, McKay JW: Topical azithromycin therapy for meibomian gland dysfunction: clinical response and lipid alterations. Cornea 2010; 29: 781-8.
36. Barabino S, Rolando M, Camicione P, et al.: Systemic linoleic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea 2003; 22: 97-101.
37. Geerling G, Tauber J, Baudouin C, et al.: The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2011; 52: 2050-64.
38. Tai MC, Cosar CB, Cohen EJ, Rapuano CJ, Laibson PR: The clinical efficacy of silicone punctal plug therapy. Cornea 2002; 21: 135-9.
39. Horwath-Winter J, Thaci A, Gruber A, Boldin I: Long-term retention rates and complications of silicone punctal plugs in dry eye. Am J Ophthalmol 2007; 144: 441-4.
40. Ervin AM, Wojciechowski R, Schein O: Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2010: CD006775.
41. Ervin AM, Wojciechowski R, Schein O: Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2010: CD006775.